Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The regimen of Tivicay (dolutegravir) and Epivir (lamivudine) would be a highly cost-effective first-line option and save a great deal.
A considerable proportion of HIV transmissions occur when someone is newly infected with the virus or has interrupted antiretroviral treatment...
The proportion of infectious disease physicians who report prescribing PrEP apparently grew substantially between 2013 and 2014.
HIV treatment’s ability to slow the spread of the virus will remain compromised without significant efforts to improve rates of engagement..
HIV-positive people diagnosed with Hodgkin’s lymphoma have excellent health prospects.
Youths who contracted HIV at birth may lack immunity to measles, mumps and rubella despite vaccination for the three diseases.
People coinfected with HIV and hepatitis C are more likely to experience rejection of a transplanted liver than those who are monoinfected wit...
Starting HIV treatment with a high viral load leads to a much greater reduction in death rates for people ages 45 to 65, compared with younger...
Drug-resistant strains of HIV continue to be transmitted in the UK, but this doesn’t appear likely to have a major effect on the treatment res...
People who recently contracted HIV may develop a vast array of symptoms, which are often serious and can be life-threatening
Various HIV antiretrovirals are linked to a raised risk of cardiovascular problems, although the overall risk of such an outcome is still low.
Daily Truvada as pre-exposure prophylaxis (PrEP) against HIV takes five to seven days to reach top estimated effectiveness among gay men.
Marijuana use among people coinfected with HIV and hepatitis C is linked with a lowered risk of insulin resistance.
A Chinese study of the real-world effects of antiretroviral treatment’s capacity to reduce the risk of HIV transmission has found it...
The herpes drug Valtrex suppressed HIV in a small trial, raising the possibility it may one day be added to the HIV antiretroviral portfolio.
The average CD4 count of HIV-positive sub-Saharan Africans upon diagnosis or starting treatment has not risen over the past decade.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.